Bank Of New York Mellon Corp Myovant Sciences Ltd. Transaction History

Bank Of New York Mellon Corp

$538 Trillion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$24.03 - $27.02 $1.38 Million - $1.55 Million	57,415 New	57,415 $1.55 Million
Q3 2022 Nov 14, 2022	SELL	$11.6 - $20.44 $1,798 - $3,168	-155 Reduced 0.59%	26,121 $469,000
Q2 2022 Aug 15, 2022	SELL	$7.78 - $14.69 $2,388 - $4,509	-307 Reduced 1.15%	26,276 $327,000
Q3 2021 Nov 12, 2021	BUY	$18.94 - $26.99 $90,912 - $129,551	4,800 Added 22.04%	26,583 $597,000
Q2 2021 Aug 11, 2021	SELL	$17.07 - $24.56 $330,167 - $475,039	-19,342 Reduced 47.03%	21,783 $495,000
Q1 2021 May 13, 2021	BUY	$20.46 - $25.18 $348,454 - $428,840	17,031 Added 70.69%	41,125 $846,000
Q4 2020 Feb 09, 2021	BUY	$13.8 - $27.62 $8,487 - $16,986	615 Added 2.62%	24,094 $665,000
Q3 2020 Nov 12, 2020	SELL	$14.05 - $22.6 $92,182 - $148,278	-6,561 Reduced 21.84%	23,479 $329,000
Q2 2020 Aug 12, 2020	SELL	$7.34 - $20.84 $7 - $20	-1 Reduced -0.0%	30,040 $619,000
Q1 2020 May 06, 2020	BUY	$6.55 - $14.76 $6 - $14	1 Added 0.0%	30,041 $226,000
Q4 2019 Feb 14, 2020	SELL	$4.2 - $19.21 $1.67 Million - $7.64 Million	-397,517 Reduced 92.97%	30,040 $466,000
Q3 2019 Nov 07, 2019	BUY	$5.19 - $9.46 $93,679 - $170,753	18,050 Added 4.41%	427,557 $2.22 Million
Q2 2019 Aug 12, 2019	SELL	$8.69 - $25.0 $61,316 - $176,400	-7,056 Reduced 1.69%	409,507 $3.71 Million
Q1 2019 May 14, 2019	BUY	$16.83 - $24.45 $795,099 - $1.16 Million	47,243 Added 12.79%	416,563 $9.94 Million
Q4 2018 Feb 11, 2019	BUY	$15.01 - $25.2 $5.37 Million - $9.01 Million	357,454 Added 3012.42%	369,320 $6.06 Million
Q1 2018 May 15, 2018	SELL	$12.46 - $21.32 $10,217 - $17,482	-820 Reduced 6.46%	11,866 $252,000
Q4 2017 Feb 09, 2018	BUY	$11.37 - $16.4 $144,239 - $208,050	12,686	12,686 $160,000

Others Institutions Holding MYOV

# of Institutions

Shares Held

61.3K

Call Options Held

Put Options Held

View Full List

About Myovant Sciences Ltd.

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

More about MYOV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account